Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Personalis Earnings Call: Key Takeaways

Personalis presented interim Victory study data for NeXT Personal, demonstrating 96% pre-surgical sensitivity and 100% detection of colorectal cancer recurrences with significant lead-time advantages.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Mgmt ConfidenceHigh confidence in ultra-sensitive detection down to 1-3 parts per million.
Demand VisibilityStudy recruitment doubled; high interest from pharma partners for clinical trials.
Op. LeverageUltra-sensitive assay reduces need for multiple blood draws, improving efficiency.
Segment Growth100% detection in both liver and traditionally difficult lung recurrence sites.
New ClientsCollaborations with BC Cancer and potential future pharmaceutical partnerships for trials.
RegulatoryMRD results currently for research; AJCC staging may eventually include CTDNA.
CommentaryUltra-sensitive detection provides six months extra lead time for clinical intervention.
New LaunchesNeXT Personal assay utilizing whole genome sequencing and 1,800 personalized variants.

Growth

96% pre-surgical sensitivity; 83.9% sensitivity in MRD window; 176-day lead time over standard imaging.

Outlook

Study continues to recruit with twice as many patients; updates and publication pending.

Risks

Clinical utility remains a research question; lack of head-to-head data against competitors; reimbursement challenges in Canada.

Source

The company's earnings call, NASDAQ: PSNL, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Personalis, Inc.: key numbers

Share price
$14.80Close, Nov 16
Market cap
$1.6B
Shares outstanding
108.4MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Personalis, Inc.

All →
4:15 PM ET Form 4
Insider Selling

Personalis CEO Christopher M. Hall Sells $462K of Stock

Christopher M. Hall, CEO, sold 29,112 shares of Personalis, Inc. at $15.87 a share, worth $462K in total on Nov 3, 2026. Shares held after the trade: 199,415 (-12.7%).

Value
$462K
Shares
29,112
Price
$15.87
Role
CEO
Holding change
-12.7%
Trade date
Nov 3, 2026
4:06 PM ET 8-K
Financial Results

Personalis Financial Results

Personalis reported Q3 2026 total revenue of $25.6 million, a significant increase from $14.5 million in the prior year, driven by growth in clinical test volume and population sequencing. The company ended the quarter with $190.6 million in cash and noted its pending merger with Tempus AI. Due to the pending acquisition, the company is no longer providing forward-looking financial guidance.

“These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians, and biopharma partners.”

Chris Hall, Chief Executive Officer of Personalis
4:06 PM ET 10-Q
Financial Results ▶ Call

Personalis Q3 2026 Results: Net Loss of $33.8M, Loss Widens

Personalis, Inc. has entered into a definitive merger agreement to be acquired by Tempus AI, Inc. The company continues to report a history of losses and maintains significant customer concentration with Moderna, the VA MVP, and Merck while focusing on its partner-centric strategy for cancer testing services.

Key figure
Net loss $33.8M
4:06 PM ET 8-K
M&A Deal

Personalis M&A Deal with Tempus AI, Inc.

Personalis announced the expiration of the Hart-Scott-Rodino (HSR) Act waiting period regarding its pending acquisition by Tempus AI, Inc. The expiration of the antitrust waiting period satisfies a key closing condition for the merger, which was originally announced on July 20, 2026. The transaction remains subject to approval by Personalis stockholders and other customary closing conditions.

Counterparty
Tempus AI, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.